Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921698 | 0.79 | TTBK1 (0.31) | PRKCIAXLKDM4EALDH1A1TTBK1 | |
| SCHEMBL23647524 | 0.71 | PRKCI (0.38) | PRKCIAXLKDM4EALDH1A1POLB | |
| SCHEMBL29478937 | 0.70 | AXL (0.41) | PRKCIAXLKDM4EALDH1A1POLB | |
| SCHEMBL23270478 | 0.70 | AXL (0.41) | PRKCIAXLKDM4EALDH1A1POLB | |
| SCHEMBL1441837 | 0.70 | PRKCI (0.57) | PRKCIAXLTTBK1TTBK2RIPK1 | |
| SCHEMBL29285160 | 0.68 | AXL (0.39) | PRKCIAXLKDM4EALDH1A1TTBK1 | |
| SCHEMBL30877385 | 0.68 | AXL (0.39) | PRKCIAXLKDM4EALDH1A1TTBK1 | |
| SCHEMBL9918658 | 0.68 | PRKCI (0.42) | PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL12684549 | 0.68 | PRKCI (0.42) | PRKCIAXLTTBK1TTBK2JAK2 | |
| SCHEMBL3492520 | 0.67 | JAK2 (0.47) | TTBK1TTBK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | PRKCI 156/4885AXL 724/4885KDM4E 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.